Avid Bioservices Inc (CDMO)

[entdoc]

golfho and threes, thanks. A few thoughts: it is the stock "run-up" price during the approval process that nets the most bang for the buck, not necessarily the final approval as such. I agree with threes that the time frame will vary so much, as will the price tag, that accurate predictions are difficult. IMO the chances of a "bust" on all products in PPHM pipeline is essentially nil. Regarding biosimilars: they are not (bio)generics, but near-copies of existing biologic medications made with a different cell lines and different manufacturing and purification process, thus final products are not identical to the precedent. The excitement generated at PPHM for biosimilars most likely relates to 2C3, a better Avastin because it is more specific. 2C3 IMO is a textbook description of a biosimilar that should be ushered through FDA regulatory channels at mach speed (or at least close to that)!